EFFECTIVENESS AND SAFETY OF BARICITINIB IN CHILDREN WITH ACTIVE JUVENILE IDIOPATHIC ARTHRITIS: A SINGLE-CENTER RETROSPECTIVE COHORT STUDY
Baricitinib, a selective Janus kinase 1 and Janus kinase 2 (JAK1/JAK2) inhibitor, was approved by the European Medicines Agency (EMA) in 2023 for the treatment of juvenile idiopathic arthritis (JIA) in children aged 2 years and older. Data on its use in routine clinical practice at Russian pediatric centers remain scar...